Key points

  • Carl L. Gordon, a director at Electra Therapeutics, Inc. (ETRA), bought $20.00 million of common stock on September 21st, 2026. The purchase covered 1,333,333 shares.
  • Every share was reported at a single price of $15.00. There is no spread to read in the tape: the price range on the buy runs from $15.00 to $15.00.
  • The buying arrived across 2 filings. Both carry the same transaction date, so this reads as one decision reported in two documents rather than a campaign spread over weeks.
  • The last price on ETRA is $12.67, below the price Gordon paid. Against a market capitalization of $795,257,344, a $20.00 million director purchase is a meaningful slice of the company.

Electra Therapeutics, Inc., a biological products name outside diagnostic substances, disclosed insider buying of $20.00 million by director Carl L. Gordon. The transaction date on the paperwork is September 21st, 2026, and the size is 1,333,333 shares.

That is the whole of the event in one line. A sitting director committed $20.00 million at $15.00 a share in a company carrying a market capitalization of $795,257,344, and the stock has since printed at $12.67.

What the filing shows

The reported price range is $15.00 to $15.00. When a Form 4 shows a single price across the entire block, it usually means the shares were taken in one transaction rather than accumulated through a series of open market fills at drifting prices. The filing record does not describe the buyer's reasoning, and neither will we.

Two filings carry the disclosure. The share count and the dollar figure reconcile to 1,333,333 shares and $20.00 million on the September 21st, 2026 date. Gordon is listed in the director role, which is the capacity that matters here: directors sit on the board, see the board materials, and file under the same Section 16 rules as officers and ten percent holders.

What the insider did

The buyer is an individual, not a fund reporting on a schedule. That distinction matters for how the purchase should be read. Institutional accumulation can reflect index mechanics, mandate changes, or allocation rules. A named director filing a Form 4 for $20.00 million is a personal, dated, disclosed commitment with a printed price attached.

The flat $15.00 price is worth holding onto. It is the reference point for everything that follows, because the market is now quoting the shares lower than that level. Purchases at a fixed price in a single session are common in financings and in negotiated blocks, and the filing itself is the only source of record for what took place.

Nothing in the disclosure speaks to intent, holding period, or any view on the business. The Form 4 documents a purchase, a date, a price, and a count. That is the full extent of what can be stated.

Where the stock sits

ETRA last traded at $12.67. Gordon paid $15.00. The insider is therefore underwater against the last print, which is a plain observation about the tape rather than a judgment about the position.

Market capitalization stands at $795,257,344. Set the $20.00 million purchase against that figure and the scale becomes clear: this is not a token board-level buy of a few thousand shares filed to satisfy ownership guidelines. It is a large absolute dollar commitment relative to the size of the issuer.

What that leaves

Three things are established by the record. A director bought. He bought 1,333,333 shares for $20.00 million. He paid $15.00 for all of them on September 21st, 2026.

Everything else belongs to the reader's own work. Biological products developers outside the diagnostics niche live and die on clinical timelines, cash runway, and regulatory decisions, none of which appear in a Form 4. The filing tells you what an insider did with his money on one day. It does not tell you what the pipeline will do next.

The gap between the $15.00 paid and the $12.67 last price is the single most concrete thing an outside investor can weigh here. It shows that the market has repriced the shares since the transaction date, and it shows that the director's entry point is above where the stock currently changes hands. Both facts sit in the open record.

Sources: SEC Form 4 filings submitted via EDGAR and reviewed by InsiderBuying.com, covering transactions dated September 21st, 2026.

Informational only, not investment advice.